FGFR2 and cholangiocarcinoma: Pemigatinib, a potent FGFR1–4 inhibitor approved by the FDA and EMA for second-line treatment of advanced cholangiocarcinoma with FGFR2 mutations, was used to treat a case of FGFR2-altered advanced gastric cancer after exhausting multiple prior treatment options, among which were docetaxel, cisplatin, irinotecan, and nivolumab.